350 related articles for article (PubMed ID: 35496822)
1. The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.
Lombardi C; Berti A; Cottini M
Curr Res Immunol; 2022; 3():42-53. PubMed ID: 35496822
[TBL] [Abstract][Full Text] [Related]
2. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
Roufosse F
Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
[TBL] [Abstract][Full Text] [Related]
4. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
5. The multiple functions and subpopulations of eosinophils in tissues under steady-state and pathological conditions.
Kanda A; Yun Y; Bui DV; Nguyen LM; Kobayashi Y; Suzuki K; Mitani A; Sawada S; Hamada S; Asako M; Iwai H
Allergol Int; 2021 Jan; 70(1):9-18. PubMed ID: 33243693
[TBL] [Abstract][Full Text] [Related]
6. Eosinophilic respiratory disorders and the impact of biologics.
Bernstein JS; Wechsler ME
Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
[TBL] [Abstract][Full Text] [Related]
7. Targeting eosinophils: severe asthma and beyond.
Caminati M; Menzella F; Guidolin L; Senna G
Drugs Context; 2019; 8():212587. PubMed ID: 31391853
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
9. Multiple Biological Aspects of Eosinophils in Host Defense, Eosinophil-Associated Diseases, Immunoregulation, and Homeostasis: Is Their Role Beneficial, Detrimental, Regulator, or Bystander?
Kanda A; Yasutaka Y; Van Bui D; Suzuki K; Sawada S; Kobayashi Y; Asako M; Iwai H
Biol Pharm Bull; 2020; 43(1):20-30. PubMed ID: 31902927
[TBL] [Abstract][Full Text] [Related]
10. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils and childhood asthma.
Choi BS
Clin Exp Pediatr; 2021 Feb; 64(2):60-67. PubMed ID: 33445830
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
13. Eosinophils and eosinophilic immune dysfunction in health and disease.
Jackson DJ; Akuthota P; Roufosse F
Eur Respir Rev; 2022 Mar; 31(163):. PubMed ID: 35082127
[TBL] [Abstract][Full Text] [Related]
14. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
15. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilic airway diseases: basic science, clinical manifestations and future challenges.
Janson C; Bjermer L; Lehtimäki L; Kankaanranta H; Karjalainen J; Altraja A; Yasinska V; Aarli B; Rådinger M; Hellgren J; Lofdahl M; Howarth PH; Porsbjerg C
Eur Clin Respir J; 2022; 9(1):2040707. PubMed ID: 35251534
[TBL] [Abstract][Full Text] [Related]
17. Type 2 innate lymphoid cells: A novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma.
Liu T; Wu J; Zhao J; Wang J; Zhang Y; Liu L; Cao L; Liu Y; Dong L
Respir Med; 2015 Nov; 109(11):1391-6. PubMed ID: 26459159
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Sinonasal Histopathological Changes in Biological Treatment of Eosinophilic Chronic Rhinosinusitis.
Ho J; Alvarado R; Rimmer J; Sewell WA; Walter S; Earls P; Campbell RG; Sacks R; Kalish LH; Harvey RJ
Am J Rhinol Allergy; 2022 Jan; 36(1):72-80. PubMed ID: 34096329
[TBL] [Abstract][Full Text] [Related]
19. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN
Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
